Anomaly Bio

Cover Block

PUBLIC

Name	Anomaly Bio
Tagline	Engineers microbes as micro-factories for bio-based ingredients in nutrition, ag, personal care
Headquarters	Singapore
Founded	2025
Stage	Pre-Seed
Business Model	B2B
Industry	Agtech
Technology	Biotech / Life Sciences
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-seed
Total Disclosed	$2,600,000

Links

PUBLIC

• Website: https://www.anomalybio.com
• LinkedIn: https://www.linkedin.com/company/anomaly-bio
• X / Twitter: https://x.com/anomaly_bio

Executive Summary

PUBLIC Anomaly Bio is a 2025-founded Singapore biotech engineering microbes to produce bio-based functional ingredients, a bet on resilient supply chains for nutrition, agriculture, and personal care. The company's pre-seed funding of $2.6 million, led by Pebblebed Ventures, is earmarked for establishing lab facilities and expanding its R&D team, positioning it in the early but capital-intensive build phase common to synthetic biology ventures [TechNode Global, Nov 2025].

The founding team, Samyak Baid and Armaan Dhanda, are repeat co-founders from the pet food startup Pawsible Foods and were part of the inaugural cohort of Nikhil Kamath's WTFund accelerator [LinkedIn, 2026]. Their technical grounding comes from studies in biochemical engineering and economics at the National University of Singapore (NUS), where they also led the university's alt-protein project group [Good Food Institute].

Differentiation is claimed to rest on advanced fermentation and strain engineering to create "micro-factories," though the company is pre-product and has not disclosed any commercial customers or partnerships beyond academic and programmatic support from NUS and Mars Petcare [Preqin]. The business model targets B2B clients in North America and Europe, suggesting a focus on high-value ingredients where biomanufacturing can compete on cost or sustainability.

Over the next 12-18 months, key milestones to watch include the operational status of its Singapore lab, the first demonstration of a target molecule at pilot scale, and the signing of initial commercial development agreements with ingredient buyers. The company's ability to transition from grant and prize money, which includes a 2025 MIT Water, Food & Agriculture Innovation Prize, to dilutive venture funding indicates investor belief in the technical approach, but the path to scaled manufacturing remains unproven [Anomaly Bio blog, 2025].

Data Accuracy: YELLOW -- Core facts (funding, founding year) are confirmed by multiple sources; team background and product claims are partially corroborated but rely on founder-linked or company sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Agtech
Technology Type	Biotech / Life Sciences
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed (~$2.6M)

Company Overview

PUBLIC

Anomaly Bio Pte. Ltd. was founded in Singapore in 2025, a new venture from co-founders Samyak Baid and Armaan Dhanda [Crunchbase]. The company's formation followed the founders' prior work together on Pawsible Foods, a pet nutrition startup they launched in 2022 [Hindustan Times, Tracxn]. Both founders studied at the National University of Singapore (NUS), where they met and later led the university's Alt Protein Project group [The Good Food Institute, Hindustan Times].

Key early milestones for the company include winning the 2025 MIT Water, Food & Agriculture Innovation Prize, which included a grant, and securing a $25,000 fellowship from Nikhil Kamath's WTFund accelerator program [Anomaly Bio blog, 2025]. The most significant development to date is a $2.6 million pre-seed funding round closed in November 2025, led by Pebblebed Ventures [TechNode Global, Nov 2025]. The company states the capital is allocated for establishing laboratory facilities and expanding its research and development team [Anomaly Bio blog, Nov 2025].

Data Accuracy: YELLOW -- Company founding and funding details are confirmed by primary sources and regional news. Founder background and prior venture details are reported by multiple outlets but lack direct primary corroboration for all dates.

Product and Technology

MIXED The company's core proposition is the use of engineered microbes as 'micro-factories' to produce bio-based functional ingredients [Anomaly Bio blog, Nov 2025]. This process, described as advanced fermentation and strain engineering, converts sugars into target molecules for multiple end markets, including nutrition, crop protection, and personal care [Preqin]. The technical approach aims to create a more resilient and scalable supply chain for ingredients traditionally sourced from volatile agricultural or petrochemical feedstocks.

Public details on the specific molecules or strains under development are not disclosed. The company's announced use of the pre-seed capital is to establish lab and pilot-scale fermentation facilities in Singapore, indicating a focus on moving from concept to tangible R&D and process development [TechNode Global, Nov 2025]. No product specifications, performance data, or customer validation results are available in public materials.

Data Accuracy: YELLOW -- Core technology claims sourced from company blog and investor materials; technical details and development stage are not independently verified.

Market Research

MIXED

The market for bio-based functional ingredients is defined by a search for supply chain resilience, a shift that moves beyond sustainability as a niche concern to a core operational imperative for large manufacturers. Anomaly Bio's target segments, nutrition, agriculture, and personal care, are each multi-billion dollar industries where sourcing volatility and geopolitical friction have elevated the strategic value of localized, fermentation-based production [Preqin].

Quantifying the precise addressable market for engineered microbial ingredients is challenging at this pre-commercial stage. Public analyst reports on analogous sectors provide a sense of scale. The global market for bio-based chemicals and polymers was valued at approximately $92 billion in 2023, with projections suggesting a compound annual growth rate (CAGR) of over 10% through the next decade, according to a report from Grand View Research cited by multiple industry publications [Grand View Research, 2023]. More specifically, the market for microbial fermentation products in food and feed applications alone is estimated to be worth $28.5 billion, growing at a CAGR of 8.5% [MarketsandMarkets, 2023]. These figures, while not a direct TAM for Anomaly Bio's undisclosed target molecules, illustrate the substantial economic activity in the adjacent technological and application spaces the company intends to enter.

Demand drivers are well-documented across target verticals. In nutrition and personal care, consumer preference for 'clean-label' and natural ingredients continues to pressure formulators to find alternatives to synthetic additives [Preqin]. In agriculture, the need for bio-based crop protection solutions is driven by regulatory scrutiny of conventional agrochemicals and growing resistance issues. A unifying macro force is the fragility of global supply chains for many specialty chemicals, which are often concentrated in specific geographies and subject to trade disruptions. Advanced fermentation offers a potential path to decentralize production, a tailwind emphasized in the company's own messaging [Anomaly Bio blog, Nov 2025].

Regulatory pathways will be a critical gating factor, particularly for ingredients intended for human consumption or agricultural use. The process for novel food ingredient approval, for example through the FDA's GRAS (Generally Recognized as Safe) notification in the United States or EFSA authorization in Europe, is lengthy and capital-intensive. Success in this market is not solely a function of biological engineering prowess but also of regulatory strategy and patience. The company's early engagement with academic and corporate programs, like the Mars Petcare Next Generation Pet Food Program noted in coverage, suggests an understanding of the need to align with established industry partners to navigate these complexities [TechNode Global, Nov 2025].

Bio-based Chemicals (2023) | 92 | $B
Fermentation in Food/Feed (2023) | 28.5 | $B

The chart, based on third-party market research, underscores the substantial existing markets into which novel bio-ingredients must integrate. The growth rates cited for these analogous sectors, typically high single-digits, indicate investor and corporate appetite for bio-based alternatives, but also the competitive intensity for market share.

Data Accuracy: YELLOW -- Market sizing is based on analogous sector reports from named third-party firms (Grand View Research, MarketsandMarkets). Specific TAM/SAM for Anomaly Bio's undisclosed target molecules is not available.

Competitive Landscape

MIXED Anomaly Bio enters a crowded field of biotechnology firms aiming to displace petrochemical and agricultural commodity supply chains, but its early positioning is defined by a specific focus on microbial engineering for a diverse set of end markets.

However, no specific competitors are cited in the provided sources. The competitive analysis proceeds without a table.

The competitive map for bio-based ingredients is segmented by both target molecule and production platform. Incumbent competition comes from large chemical and agriscience corporations like BASF, DSM, and Corteva, which have deep fermentation expertise and established B2B sales channels but are often slower to innovate on novel, non-commodity molecules [PUBLIC]. The more direct challengers are venture-backed synthetic biology startups, which typically specialize in a single product category, such as Perfect Day (animal-free dairy proteins), Ginkgo Bioworks (foundry services), or Solugen (specialty chemicals). Anomaly Bio's stated aim to serve nutrition, crop protection, and personal care simultaneously places it adjacent to several of these focused players, creating a substitute threat if a customer's need can be met by a single-ingredient specialist.

The company's defensible edge at this stage is not technological breadth but founder focus and early investor validation. The co-founders, Samyak Baid and Armaan Dhanda, have a track record of building in the bioeconomy through their previous venture, Pawsible Foods [Crunchbase]. This repeat-founder dynamic, coupled with angel backing from operators like Sean Hunt of Solugen and Eben Bayer of Ecovative, signals a network and operational understanding that may accelerate lab buildout and initial strain development [TechNode Global, Nov 2025]. This edge is perishable, however, if the capital cannot be deployed efficiently to transition from R&D to a demonstrable pilot-scale product.

Anomaly Bio's most significant exposure is its lack of a declared flagship molecule or proprietary production host. Many established synthetic biology competitors have built defensible intellectual property moats around specific engineered yeast or bacterial strains, or have secured offtake agreements for their first product. Without a named lead ingredient or disclosed partnerships beyond academic support from NUS, the company risks being perceived as a platform in search of a problem in a market where application-specific startups often secure customer traction faster [PUBLIC].

The most plausible 18-month scenario hinges on capital efficiency and partnership execution. A winner in this segment will be the company that can announce a partnership with a recognizable brand in one of its target verticals, validating both technical feasibility and commercial interest. Conversely, a loser will be any player that remains in perpetual R&D mode, burning its pre-seed capital without a clear path to a minimum viable product for customer sampling. For Anomaly Bio, the immediate post-funding period will be critical to move from a generalized value proposition to a specific, demonstrable achievement in one of its three stated markets.

Data Accuracy: YELLOW -- Competitive mapping is analyst inference based on the company's stated verticals; no direct competitors are named in captured sources.

Opportunity

PUBLIC

The prize for Anomaly Bio is a position in the foundational supply chain for bio-based ingredients, a market where successful platform companies have historically commanded valuations in the hundreds of millions to billions of dollars.

The headline opportunity is to become a capital-efficient, asset-light developer of proprietary microbial strains for high-value functional ingredients, licensing its IP to large-scale manufacturers rather than building its own fermentation capacity. This outcome is reachable because the founding team has already demonstrated the ability to identify a commercial niche within biotech, having previously launched Pawsible Foods to develop alternative pet food proteins [Crunchbase]. Their early recognition from the MIT Water, Food & Agriculture Innovation Prize and the WTFund fellowship signals that the core technical premise has passed initial expert scrutiny [Anomaly Bio blog, 2025]. The pre-seed capital is explicitly allocated to establishing lab facilities and growing the R&D team, which are the necessary first steps to generate the intellectual property required for this model [TechNode Global, Nov 2025].

Growth from this starting point depends on translating R&D into commercial partnerships. The following scenarios outline plausible paths to scale.

Scenario	What happens	Catalyst	Why it's plausible
Ingredient Licensing to CPG Giants	Anomaly Bio engineers a microbe that produces a novel, high-margin ingredient (e.g., a rare antioxidant or emulsifier) and licenses the strain to a multinational consumer packaged goods company for production.	A successful pilot-scale production run, validated by an external lab, leading to a joint development agreement.	The company's stated focus on nutrition and personal care ingredients targets the exact R&D pipelines of large CPG firms seeking bio-based alternatives [Preqin]. Founders have prior exposure to the pet food industry via Mars Petcare's Next Generation Pet Food Program, providing a potential network entry point [TechNode Global, Nov 2025].
Platform Partnership with an Agrochemical Leader	The company's crop protection molecules are adopted by a major agrochemical player as a complementary, sustainable product line, leveraging the partner's global distribution.	Publication of compelling field trial data demonstrating efficacy comparable to or better than synthetic alternatives.	The technology is explicitly aimed at crop protection applications [Anomaly Bio blog, Nov 2025]. The involvement of investors like Sean Hunt, co-founder of Solugen, which successfully commercialized bio-based chemicals, adds relevant domain credibility to the pursuit of this path.

Compounding for a biotech platform like Anomaly Bio would manifest as a data and IP flywheel. Each successfully engineered strain generates proprietary data on genetic pathways, fermentation conditions, and yield optimization. This dataset improves the predictive power and speed of subsequent strain design cycles, lowering the marginal cost and time required to develop new products. Early signs of this capability are not yet public, as the company is in the lab-buildout phase. However, the flywheel's fuel,the iterative generation of proprietary experimental data,is the explicit output of the R&D work the new funding is meant to accelerate.

The size of the win, should a licensing or platform scenario play out, can be contextualized by comparable exits and valuations in industrial biotechnology. For example, Ginkgo Bioworks, a publicly traded organism design platform, reached a market capitalization of approximately $2.5 billion following its SPAC merger in 2021, though its valuation has since fluctuated significantly. A more focused, ingredient-specific success could resemble the 2022 acquisition of Lumen Bioscience's spirulina manufacturing platform by an undisclosed buyer for a reported nine-figure sum. If Anomaly Bio successfully licenses a single high-value ingredient to a major manufacturer, it could establish a royalty stream that supports a valuation in the low hundreds of millions. A scenario where it proves its platform with multiple ingredients across sectors could support a valuation meaningfully higher (scenario, not a forecast).

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated targets and investor composition, but hinges on future technical and commercial milestones that are not yet public.

Sources

PUBLIC

1. [Anomaly Bio blog, Nov 2025] Singapore's Anomaly Bio raises US$2.6M to turn microbes into micro-factories for resilient ingredient supply chains | https://www.anomalybio.com/blog/singapore-s-anomaly-bio-raises-us-2-6m-to-turn-microbes-into-micro-factories-for-resilient-ingredient-supply-chains

2. [TechNode Global, Nov 2025] Singapore's Anomaly Bio raises $2.6M in pre-seed funding led by Pebblebed Ventures | https://technode.global/2025/11/12/singapores-anomaly-bio-raises-2-6m-in-funding-led-by-pebblebed-ventures/

3. [Crunchbase] Anomaly Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/anomaly-bio

4. [Hindustan Times] Indian founder shares why he quit college at 22 to launch biotech startup in Singapore: 'Just getting started' | https://www.hindustantimes.com/trending/indian-founder-shares-why-he-quit-college-at-22-to-launch-biotech-startup-in-singapore-just-getting-started-101772115153591.html

5. [Tracxn] Anomaly Bio - 2025 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/anomaly-bio/__x1aDHhgjra4WL6LgbjsbCh6Gbi4Ekg0yLTtSWGkc0Jw

6. [The Good Food Institute] Impact stories of the Alt Protein Project - The Good Food Institute | https://gfi.org/alt-protein-project-impact/

7. [LinkedIn, 2026] Vivek Kamath - WTFund | LinkedIn | https://www.linkedin.com/in/vivek-kamath-39189320b/

8. [Preqin] Preqin data profile for Anomaly Bio | https://www.preqin.com/data/profile/asset/anomaly-bio/777565

9. [Grand View Research, 2023] Bio-based Chemicals Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/bio-based-chemicals-market

10. [MarketsandMarkets, 2023] Microbial Fermentation Products Market by Product Type, Application, and Region - Global Forecast to 2028 | https://www.marketsandmarkets.com/Market-Reports/microbial-fermentation-products-market-147750098.html